Physician profile
Thomas J Wente
NPI 1538134002
$8,956.27
in general payments reported to CMS, 2019-2025
45 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $977 · 2021: $1,749 · 2022: $1,196 · 2023: $1,028 · 2024: $1,320 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,692 · Education: $97.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.79 |
| Education | $97.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,733.30 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,146.04 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $981.66 | 2019-2025 | |
| Amgen INC. | $740.10 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $649.50 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $398.46 | 2019-2024 | Jardiance, Emgality, Zepbound |
| Glaxosmithkline, LLC. | $365.39 | 2019-2025 | Bexsero, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $347.67 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $247.96 | 2020-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $235.29 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $222.62 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.93 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Esperion Therapeutics, INC. | $170.70 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $162.88 | 2019-2025 | |
| Radius Health, INC. | $145.82 | 2019-2025 | Tymlos |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.